Boston, Massachusetts 2021-05-24 11:27:30 –
Vaccinations are ongoing throughout the United States and are intended for children up to the age of 12, but how effective each vaccine is and when do you need a booster shot at some point?
According to medical professionals, each of the three vaccines currently available provides protection.
The breakdown is as follows.
How long will the Pfizer vaccine last? How about Moderna?
Pfizer and BioNTech previously stated that data from the Phase 3 trial showed a high level of protection against COVID 6 months after the second dose.
Studies also suggest protection of the Moderna vaccine The give to COVID-19 lasts at least 6 months.
Both reports were based on follow-up tests of dozens of people who received shots during a study that led to the use of the vaccine. These studies were conducted before new variants or versions of the coronavirus emerged and began to spread.
How effective is the COVID vaccine?
In clinical trials, Moderna’s vaccine reported 94.1% efficacy in preventing COVID-19 in people who received both doses. The Pfizer-BioNTech vaccine is said to be 95% effective.
A new CDC study reported that a single dose of Pfizer or Moderna’s COVID vaccine was 80% effective in preventing infection. That number jumped to 90% two weeks after the second dose, a study of vaccinated health care workers showed.
“These findings indicate that the approved mRNA COVID-19 vaccine is effective in preventing SARS-CoV-2 infection among adults of production age in real-world conditions, regardless of symptom status. It shows that, “the US institution wrote in a study. “COVID-19 vaccination is recommended for all eligible individuals.”
The Pfizer vaccine is currently the only vaccine approved for use in children up to the age of 12, and has been highly effective in adolescence.
In late March, Pfizer released preliminary results of a vaccine study of 2,260 US volunteers between the ages of 12 and 15. COVID-19 (New Coronavirus Infection) Of the fully vaccinated adolescents, 18 were given dummy shots.
More interestingly, researchers found that children developed antibodies that fight higher levels of the virus than previous studies measured in young adults.
The FDA said J & J’s vaccine provides strong protection against the most important things, such as serious illness, hospitalization and death. In a large study across three continents, a single dose provided 85% protection against the most serious COVID-19 disease. Defense was also strong in countries where the most worrisome variants are endemic, such as South Africa.
The CDC reports that the J & J / Janssen vaccine was 66.3% effective in a clinical trial to prevent COVID-19 infection in people who had no evidence of infection two weeks after vaccination.
“The vaccine was highly effective in preventing hospitalization and death in sick people,” said the CDC. “People infected with COVID-19 at least 4 weeks after receiving the J & J / Janssen vaccine did not need to be hospitalized.”
It is unclear whether any of the three vaccines will prevent the spread of the virus by asymptomatic people, but the CDC said, “Early evidence suggests that the J & J / Janssen vaccine may provide protection against asymptomatic infections. It suggests that there is. “
Overall efficacy data may suggest that J & J candidates are not as potent as the double-dose Pfizer and Modana options, but all COVID-19 vaccines in the world have been tested differently. It is almost impossible to compare. CNBC report.
Do you need a booster shot?
COVID-19 booster shots may be needed for fully vaccinated people within a year, according to CNBC, the top Vaccine regulator of the Food and Drug Administration on Tuesday. Report..
Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, said: During a virtual press conference with high school and junior high school journalists.
“But we don’t know yet,” he added. “Maybe more, maybe a little less … this is something we have to understand as we progress.”
Vaccine efficacy questions have been paired with an increasing prevalence of multiple COVID variants.
So far, studies have suggested that the vaccines currently in use can recognize new mutants, May not provide too much protection Against new strains.
However, Pfizer’s latest research suggests that the vaccine is effective against the coronavirus mutant that first appeared in South Africa.
“These data also provide the first clinical results that the vaccine can effectively protect from the mutants that are currently circulating. This is to reach herd immunity and end this pandemic of the world’s population. It’s an important factor, “said Ugur Sahin, CEO and co-founder of BioNTech. statement.
But Sahin I told CNBC in a recent interview Researchers say they see a decline in antibody response to the virus after eight months.
“Providing a boost can actually amplify the antibody response beyond the initial level, providing real comfort for protection of at least 12 months, and perhaps 18 months.” Sahin said. “And this is very important in an era when all variants are emerging.”
Mid-March, CNBC reported J & J Shot showed 64% efficacy in South Africa, where the more contagious and toxic B.1.351 variant spread rapidly.
Still, White House Chief Advisor Dr. Anthony Fauci said in an interview with MSNBC’s Medi Hasan last month that people may need to get booster shots within a year.
Pfizer CEO Albert Bourla also previously said that a third dose is likely to be needed within 12 months of being fully vaccinated.
New versions of boosters and vaccines that target mutants have already been investigated.
Pfizer-BioNTech is testing a third booster shot of the vaccine against fully vaccinated people.
“The flexibility of our unique mRNA vaccine platform allows us to technically develop booster vaccines within a few weeks if needed,” Sahin said. release..
Moderna is also testing the potential third dose of the current vaccine and the potential for booster shots specifically targeting South African variants. Citing early data, the company recently stated that the booster vaccine produced a promising immune response against the first identified B.1.351 and P.1 mutants in South Africa and Brazil, respectively.
Meanwhile, Johnson & Johnson CEO Alex Gorsky Interview with CNBC’s Squawk Box Earlier this month, the company was in a good position to adapt the vaccine to its variants and is working on software that “helps address some of these newly emerging variants.”
“We continue to try to predict what will happen,” said Dr. Ngozi Ezike, director of public health in Illinois, last week. “Again, boosters don’t even know when it will be, when it will be, whether it will be a new vaccine, or even the same vaccine.”
Efficacy and Potential for Booster Shots – NBC Boston Source link Efficacy and Potential for Booster Shots – NBC Boston